{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:47:15Z","timestamp":1792086435178,"version":"4.4.0"},"reference-count":4,"publisher":"BMJ","license":[{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.bmj.com\/company\/legal-information\/terms-conditions\/legal-information\/tdm-licencepolicy"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ"],"DOI":"10.1136\/bmj-2026-101150","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T13:30:15Z","timestamp":1792071015000},"page":"e101150","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["NICE rejects breast cancer drug over cost"],"prefix":"10.1136","volume":"395","author":[{"given":"Rosa","family":"Furneaux","sequence":"first","affiliation":[{"name":"The BMJ"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,10,15]]},"reference":[{"key":"2026101510250587000_395.oct15_6.e101150.1","unstructured":"National Institute for Health and Care Excellence. Final draft guidance: Inavolisib with palbociclib and fulvestrant for treating recurrent oestrogen receptor-positive HER2-negative PIK3CA-mutated advanced breast cancer after adjuvant endocrine treatment. 15 Oct 2026. https:\/\/www.nice.org.uk\/guidance\/indevelopment\/gid-ta11519\/consultation\/html-content-10"},{"key":"2026101510250587000_395.oct15_6.e101150.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2501796"},{"key":"2026101510250587000_395.oct15_6.e101150.3","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2026-100894"},{"key":"2026101510250587000_395.oct15_6.e101150.4","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2026-100896"}],"container-title":["BMJ"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/data.bmj.org\/tdm\/10.1136\/bmj-2026-101150","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmj-2026-101150","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:25:12Z","timestamp":1792085112000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.bmj.com\/lookup\/doi\/10.1136\/bmj-2026-101150"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,15]]},"references-count":4,"alternative-id":["10.1136\/bmj-2026-101150"],"URL":"https:\/\/doi.org\/10.1136\/bmj-2026-101150","relation":{},"ISSN":["1756-1833"],"issn-type":[{"value":"1756-1833","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,15]]}}}